Dianthus Therapeutics, Inc. (FRA:87E)

Market Cap	5.37B +705.7%
Revenue (ttm)	1.67M -60.8%
Net Income	-168.27M
EPS	-3.60
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	95.00
Previous Close	94.00
Day's Range	95.00 - 95.00
52-Week Range	19.90 - 99.50
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 5, 2026

About Dianthus Therapeutics

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell functio...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2019
• Employees: 92
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 87E

Financial Performance

In 2025, Dianthus Therapeutics's revenue was $2.04 million, a decrease of -67.35% compared to the previous year's $6.24 million. Losses were -$162.34 million, 91.1% more than in 2024.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error